Morgan Stanley downgraded Immunocore (IMCR) to Equal Weight from Overweight with a price target of $35, down from $74. While the firm continues to give full credit for Kimmtrak, it has lowered its assumptions on launch timing and pricing for brenetafusp, given disappointing data earlier this year in cutaneous melanoma and ovarian cancer. The analyst sees limited upside potential from additional brenetafusp updates as the company continues signal detection in metastatic NSCLC and combination in earlier line NSCLC
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore, EORTC announce enrollment of first patient in Phase 3 ATOM trial
- Immunocore downgraded to Neutral from Outperform at Mizuho
- Immunocore Holdings Prepares Early Loan Agreement Termination
- Immunocore Holdings Plc Reports Strong Q3 Revenue Growth
- Immunocore reports Q3 EPS 17c, consensus (35c)